Bank of New Hampshire Sells 666 Shares of CVS Health Co. (NYSE:CVS)

Bank of New Hampshire decreased its holdings in shares of CVS Health Co. (NYSE:CVSFree Report) by 41.9% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 925 shares of the pharmacy operator’s stock after selling 666 shares during the quarter. Bank of New Hampshire’s holdings in CVS Health were worth $74,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in CVS. V Square Quantitative Management LLC boosted its stake in CVS Health by 2,763.2% during the 3rd quarter. V Square Quantitative Management LLC now owns 3,035 shares of the pharmacy operator’s stock valued at $212,000 after purchasing an additional 2,929 shares during the period. Acadian Asset Management LLC raised its holdings in CVS Health by 4.3% in the 3rd quarter. Acadian Asset Management LLC now owns 317,865 shares of the pharmacy operator’s stock valued at $22,192,000 after acquiring an additional 13,224 shares in the last quarter. Motley Fool Asset Management LLC raised its holdings in CVS Health by 9.0% in the 3rd quarter. Motley Fool Asset Management LLC now owns 33,013 shares of the pharmacy operator’s stock valued at $2,305,000 after acquiring an additional 2,723 shares in the last quarter. Mystic Asset Management Inc. raised its holdings in CVS Health by 4.0% in the 3rd quarter. Mystic Asset Management Inc. now owns 16,284 shares of the pharmacy operator’s stock valued at $1,137,000 after acquiring an additional 621 shares in the last quarter. Finally, Federated Hermes Inc. raised its holdings in CVS Health by 11.0% in the 3rd quarter. Federated Hermes Inc. now owns 1,200,978 shares of the pharmacy operator’s stock valued at $83,852,000 after acquiring an additional 119,415 shares in the last quarter. Institutional investors own 80.66% of the company’s stock.

CVS Health Stock Up 0.7 %

NYSE CVS opened at $61.44 on Friday. The stock has a fifty day moving average of $60.47 and a 200-day moving average of $70.66. The stock has a market capitalization of $77.13 billion, a P/E ratio of 10.80, a price-to-earnings-growth ratio of 0.58 and a beta of 0.53. CVS Health Co. has a 52 week low of $52.77 and a 52 week high of $83.25. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.61 and a current ratio of 0.81.

CVS Health (NYSE:CVSGet Free Report) last released its earnings results on Wednesday, May 1st. The pharmacy operator reported $1.31 EPS for the quarter, missing the consensus estimate of $1.69 by ($0.38). The firm had revenue of $88.44 billion during the quarter, compared to analyst estimates of $89.33 billion. CVS Health had a net margin of 2.03% and a return on equity of 13.53%. The firm’s quarterly revenue was up 3.7% on a year-over-year basis. During the same period last year, the business posted $2.20 earnings per share. On average, equities research analysts forecast that CVS Health Co. will post 7.02 EPS for the current year.

Insider Activity

In other news, Director Edward J. Ludwig bought 1,000 shares of the stock in a transaction dated Thursday, May 2nd. The stock was bought at an average cost of $53.88 per share, with a total value of $53,880.00. Following the purchase, the director now owns 21,630 shares of the company’s stock, valued at $1,165,424.40. The purchase was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.24% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the company. SVB Leerink reaffirmed a “market perform” rating and issued a $60.00 price target (down previously from $87.00) on shares of CVS Health in a report on Wednesday, May 1st. Argus cut their target price on CVS Health from $100.00 to $80.00 and set a “buy” rating for the company in a research report on Wednesday, May 8th. Mizuho cut their target price on CVS Health from $86.00 to $72.00 and set a “buy” rating for the company in a research report on Thursday, May 2nd. UBS Group downgraded CVS Health from a “buy” rating to a “neutral” rating and cut their target price for the stock from $85.00 to $60.00 in a research report on Thursday, May 2nd. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $58.00 target price on shares of CVS Health in a research report on Wednesday, June 12th. Eleven analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $75.05.

View Our Latest Research Report on CVS

CVS Health Profile

(Free Report)

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.

Read More

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVSFree Report).

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.